Trial site
Kobe City Medical Center General Hospital
Hyōgo, 650-0047, JapanNot linked to an institution yet
- 7running trials
- 2closed trials
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 22 trials
- Phase 1/21 trial
- Status
- Active, not recruiting5 trials
- Completed2 trials
- Recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche2 trials
- Incyte Biosciences Japan GK2 trials
- Ono Pharmaceutical Co., Ltd.2 trials
- Cytokinetics1 trial
- Gilead Sciences1 trial
- and 1 more
Running trials
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Contact: North America Clinical Trial Support Desk
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06263478· Phase 3· Incyte Biosciences Japan GK· Source
Active, not recruiting
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· Phase 3· Cytokinetics· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Active, not recruiting
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007· Phase 1/2· Incyte Biosciences Japan GK· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error